ArticleBlood cancer journal2026

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial.

Hiroshi Ureshino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.